CRYSTAL LAKE, Ill., September 23, 2024--Aptar’s N-Sorb Nitrosamine Mitigation Solution Accepted to US FDA’s Emerging Technology Program
Key Insights The projected fair value for AptarGroup is US$187 based on 2 Stage Free Cash Flow to Equity Current share...
Hedi Tlili, Segment President of AptarGroup Inc (NYSE:ATR), sold 1,375 shares of the company on September 13, 2024.